UM

Browse/Search Results:  1-2 of 2 Help

Selected(0)Clear Items/Page:    Sort:
A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing Review article
2022
Authors:  Xin-Zhu Chen;  Rong Guo;  Cong Zhao;  Jing Xu;  Hang Song; et al.
Favorite | TC[WOS]:11 TC[Scopus]:13  IF:4.4/5.0 | Submit date:2023/01/30
Anti-cancer Therapy  Crispr/cas9  Ethics  Gene Editing Technology  Off-target Effect  
Toosendanin, a novel potent vacuolar-type H+-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy Journal article
Dong, Yu, Zhu, Guoyuan, Wang, Sheng Fang, Keon, Kristine A., Rubinstein, John L., Zeng, Si Xin, Zhang, Shuang, Chen, Qiu Ling, Fu, Jing, Li, Min, Shen, Han Ming, Lu, Jin Jian, Chen, Xiu Ping, Lu, Jia Hong. Toosendanin, a novel potent vacuolar-type H+-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy[J]. International Journal of Biological Sciences, 2022, 18(7), 2684-2702.
Authors:  Dong, Yu;  Zhu, Guoyuan;  Wang, Sheng Fang;  Keon, Kristine A.;  Rubinstein, John L.; et al.
Favorite | TC[WOS]:18 TC[Scopus]:19  IF:8.2/8.3 | Submit date:2022/07/20
Toosendanin  V-atpase Inhibitor  Autophagy Inhibitor  Protective Autophagy  Anti-cancer Effect